Cagrilintide (Long-Acting Amylin Analogue) Research Overview

Simplified Summary

Cagrilintide is a fatty acid-acylated amylin analogue designed to extend the plasma half-life of amylin receptor agonist activity. Preclinical research has examined its effects on satiety-related neural circuits, gastric emptying rate, and circulating metabolic markers in animal model systems.

The combination of cagrilintide with semaglutide, studied as CagriSema, has been an active area of preclinical investigation. Researchers have used animal models to examine whether amylin and GLP-1 receptor co-activation produces additive or synergistic effects on body weight, food intake, and metabolic parameters.

Key Findings Reported in Preclinical Models

• Sustained reduction in food intake in animal model feeding studies, with extended half-life enabling prolonged suppression of meal-stimulated food consumption.
• Delayed gastric emptying in preclinical gastrointestinal motility studies using radiolabelled meal tracers.
• Body weight and adipose mass reductions in diet-induced obesity rodent models.
• Enhanced metabolic outcomes in CagriSema combination studies, with greater reductions in body weight and food intake relative to either compound alone.
• Modulation of hypothalamic neuropeptide expression including AgRP and POMC in response to dosing.
• Preservation of lean body mass in preclinical weight loss model studies.

Introduction

Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells, acting through receptor complexes formed by calcitonin receptors and receptor activity-modifying proteins. Cagrilintide was engineered as a fatty acid-acylated amylin analogue to achieve a significantly extended half-life, suitable for chronic dosing in preclinical models.

The preclinical research rationale draws on the complementary metabolic effects of amylin and GLP-1 receptor agonism through distinct hypothalamic and brainstem circuits. This mechanistic complementarity motivated preclinical CagriSema combination studies.

Research Applications

• Satiety signalling research characterising central nervous system circuits modulated by sustained amylin receptor engagement.
• Gastric motility and gastrointestinal physiology studies in animal models.
• Combination pharmacology research pairing cagrilintide with semaglutide in diet-induced obesity rodent models.
• Amylin receptor biology research in in vitro and animal model systems.